




## Neogap's EpiTCer technology contributes to a study in *Cell* advancing the understanding of multiple sclerosis

Neogap Therapeutics AB, a Swedish biotechnology company developing personalised cancer immunotherapy, has contributed to a new study published in the scientific journal *Cell*. The study presents a possible mechanism linking Epstein–Barr virus (EBV) and multiple sclerosis (MS), offering insight into a long-standing question in MS research.



The study, entitled “*Anoctamin-2-specific T cells link Epstein–Barr virus to multiple sclerosis*”, describes how certain T cells activated by Epstein–Barr virus, a common herpesvirus, can also react to a protein in the central nervous system. The researchers identify an immunological mechanism that helps explain the link between EBV infection and the development of MS.

The study presents the first mechanistic evidence showing how EBV-specific CD4<sup>+</sup> T cells can target the MS autoantigen ANO2, thereby establishing an immunological link between EBV infection and neuroinflammation. The work was led by Professor Tomas Olsson, with Assistant Professor Olivia Thomas as the first author. Both are based at the Department of Clinical Neuroscience at Karolinska Institutet, and the research reflects an extensive academic collaboration.

Neogap contributed to the study by applying the method for detecting antigen-specific T cells, originally developed by Associate Professor Hans Grönlund's research group at Karolinska Institutet. Hans Grönlund, CSO and founder of Neogap Therapeutics, is one of the senior authors on the *Cell* publication, together with additional co-authors who are affiliated with Neogap.

In this work, antigen-coupled particles were used to analyse highly specific T cell responses relevant to the study's central research question. The method is based on principles that underpin Neogap's EpiTCer® technology.

The findings contribute to a deeper understanding of T cell-driven mechanisms in autoimmune diseases. They build on earlier research in the field, where Neogap's technology has enabled the identification and characterisation of autoantigens in MS and provided insights into the link between EBV and MS. The study further illustrates how Neogap's patented technology and IP can be applied in advanced, independent research beyond the company's own development programmes.

### **EpiTCer® – Neogap's technology for precise analysis of T cell responses**

EpiTCer® is Neogap's patented technology for identifying and analysing highly specific T cell responses. The technology is based on controlled presentation of selected antigens and enables the study of rare, antigen-specific T cells with high sensitivity. EpiTCer® is used in both Neogap's internal development programmes and academic collaborations, demonstrating the platform's broad applicability and long-term relevance in immunology.

"Having our technology used in research published in *Cell* is a clear endorsement of its scientific quality. For Neogap, this is about building a long-term, relevant technology and IP platform, where strong academic collaborations are a key component," says Samuel Svensson, CEO of Neogap Therapeutics.

### **Publication reference:**

Thomas O. et al. *Anoctamin-2-specific T cells link Epstein–Barr virus to multiple sclerosis. Cell* (2026).

<http://www.sciencedirect.com/science/article/pii/S0092867425014813>

**Neogap co-authors on the publication:** Hans Grönlund, Guro Gafvelin, Birce Akpınar and Ola Nilsson.

### **Karolinska Institutet press release:**

[New mechanism links Epstein–Barr virus to MS](#)



*Project reference number: 190185439 – NEOpTTL. Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or EISMEA. Neither the European Union nor the granting authority can be held responsible for them.*

### **For more information, please contact:**

Samuel Svensson, CEO

Email: [samuel.svensson@neogap.se](mailto:samuel.svensson@neogap.se)

Phone: +46 733 54 21 94

### **About Neogap Therapeutics**

Neogap Therapeutics is a Swedish clinical-stage biotechnology company focused on developing personalised cancer immunotherapy using the patient's own cells. The therapy is based on the company's two technologies PIOR® and EpiTCer®. PIOR® is sophisticated software that uses DNA sequencing data from the patient and machine learning algorithms to select tumour-specific mutations. Then, EpiTCer® is used to multiply T cells that can recognize and attack the selected tumor-specific targets. Neogap is located at Cancer Center Karolinska in Stockholm. To learn more about Neogap and its cutting-edge research, please visit [neogap.se](http://neogap.se) and follow Neogap on [LinkedIn](#).